Pfizer Says Meningococcal Vaccine Accepted for FDA Review

Pfizer says the US Food and Drug Administration accepted for review a Biologics License Application for its investigational pentavalent meningococcal vaccine candidate, known as MenABCWY, according to a statement.

• Pfizer submitted MenABCWY for the prevention of meningococcal disease caused by the most common serogroups in individuals aged 10-25 years
  • FDA’s decision on the pentavalent meningococcal vaccine application is expected in October 2023
• If approved, the vaccine could help simplify the meningococcal vaccination schedule and provide the broadest serogroup coverage of any meningococcal vaccine, Pfizer says

To view the source of this information, click here

To contact the reporter on this ...